Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma

Nivedita Arora, Arjun Gupta, Navid Sadeghi

Research output: Contribution to journalArticle


Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.

Original languageEnglish (US)
Article numberbcr-2017-222063
JournalBMJ Case Reports
Publication statusPublished - 2017



  • HIV / AIDS
  • malignant and benign haematology

ASJC Scopus subject areas

  • Medicine(all)

Cite this